Background Eosinophilic fasciitis (EF) is a rare disorder characterized by symmetrical skin induration of the limbs, peripheral eosinophilia, and characteristic histopathological changes in the muscular fascia. Although it has been considered as a disorder limited to the skin and soft tissues, there is evidence of immunological abnormalities and visceral involvement in some patients. Objectives To study the spectrum of clinical and immunological manifestations, response to treatment and long-term outcome of patients with EF diagnosed in a tertiary Spanish hospital. Methods All the patients diagnosed with EF during the period 1983-2013 were included. Demographic, clinical, immunological, therapeutic and outcome data were obtained by reviewing the medical records and analyzed using the statistical software SPSS 21.0. Results A total number of 18 patients were included, 61% males, with a mean age at diagnosis of 51 years (range: 28-76). The onset was acute in 33% and subacute in 67%, and mean delay in diagnosis was 8±6.3 months. There was a history of physical exertion in 33% and occupational exposure to chemicals in 17%. Fever and constitutional symptoms were present in 22% of cases. The most common cutaneous manifestation was induration (89%), followed by edema (67%), hyperpigmentation (56%), erythema (39%), sclerodactyly (22%), `groove” sign (22%), pruritus (17%) and “orange peel” (11%). There was overlap with other forms of localized scleroderma in 3 cases (linear scleroderma 2, generalized morphea 1). The most common extracutaneous manifestations were musculoskeletal (arthralgia 56%, joint contractures 44%, myalgia 33%, and muscle weakness 22%). Carpal tunnel syndrome was detected in 22%, esophageal dysmotility in 11%, autoimmune thyroiditis in 6% and mild ventilatory restriction in 6%. Up to 49% showed increased acute phase reactants and 78% eosinophilia. The most common immunological abnormalities were the presence of antinuclear (28%),anti-thyroperoxidase (6%), and anti-parietal cells (11%) antibodies, and polyclonal hypergammaglobulinemia (33%). The fascia biopsy, performed in 10 cases, was consistent with EF in all them. Glucocorticoids were administered in 89%, anti-H2 22%, colchicine 17%, hydroxychloroquine 33%, methotrexate 22% and azathioprine 17%. Response to glucocorticoids was partial in all the cases. Remission was achieved with the immunosuppressive drugs in 33%, partial response in 33% and failure in 11%. A refractory case responded to PUVA photochemotherapy. After a follow-up period of 16±9.2 years of 16 cases, none of them progressed to systemic sclerosis, but 1 patient developed recurrent eosinophilic pneumonia and 1 died of a ruptured aortic aneurysm. Conclusions Extracutaneous manifestations are common in EF, especially musculoskeletal, and a small proportion of patients may develop visceral involvement, including the digestive and respiratory systems. The response to steroid therapy is not optimal in all the cases and frequently require immunosuppressive drugs. However, long-term p...
BackgroundIn De Quervain's disease (DQD), as well as many other mechanical musculoskeletal conditions, patients have therapeutic expectations that clinicians find difficult to fulfil in the short term. Due to that, it is not uncommon that patients modify, increase doses or interrupts treatments. In order to improve the management of DQD we must understand what the real rate of therapeutic adherence is and why patients disobey or interrupts the facultative prescriptions.ObjectivesTo determine proportions of different levels of therapeutic adherence in patients diagnosed by DQD and its causes.MethodsProspective study, common clinical practice-based. Patients diagnosed by DQD where contacted 5 to 7 days after been assessed by the first time. DQD diagnostic identification was performed using the electronic registry of the A&E department. Patients included visited our department from October 2012 to March 2014 (18 months). During the phone contact, patients were required to answer if they accomplished the faculty prescription at all or in 25% intervals of the full prescription (0-25%, 25 to 50%, 50 to 75% and 75 to 100%). Causes of leak of adherence to treatments were analyzed separately: Immobilization splint or ferula (IS), non-steroidal anti-inflammatory drugs (NSAIDs) and percutaneous NSAIDs (pNSAIDs).Results69 patients were contacted by phone. Treatments delivered were 65/69 IS, 39/69 NSAIDs and 29/69 pNSAIDs. No patient was instructed to combine NSAIDs and pNSAIDs. 92% of IS intervention got more than 75% adherence. The same magnitude was reached by 38.4% of NSAID and 96.5% of pNSAID intervention groups (P<0.0001, OR 54.13 95% CI [6.694 to 437-8] for pNSAID-NSAID and P=0.6624, OR 2.333 95% CI [0.2601 to 20.93] for pNSAID-SI comparisons, respectively). 18 patients in the NSAID intervention group got an adherence rate between 50 and 75%. From them, 16 pointed their lack of adherence to the persistence of symptoms and 2 tp adverse events (hypertension and gastric issues). 6 patients treated with NSAIDs and 1 treated with pNSAID got an adherence rate less than 50%. These NSAIDs intervention group pointed their lack of adherence to the persistence of symptoms. The single patient of the pNSAID intervention group abandoned the treatment due to an allergic local reaction.ConclusionsOur study points that systemic treatment of patients with DQD has the higher lack of adherence compared with physical immobilization and percutaneous administration of NSAIDs due to its worst therapeutic results in the short term (insufficient pain control). Although our study no dot discriminates the kind of NSAID intervention, our data shows that in any case, percutaneous treatment has more probabilities to reach a therapeutic adherence higher than 75%. By the other hand, it is well known that adherence is not the same that therapeutic success, however, percutaneous interventions could ensure an enough adherence, an essential requisite to decide if an intervention has been really of not successful.Disclosure of InterestNone declared
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.